International Normalized Ratio

• 

  Subject Areas on Research

  • A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). 
  • A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. 
  • A pharmacogenetic versus a clinical algorithm for warfarin dosing. 
  • A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. 
  • Acute Hepatic Failure and Nutrition. 
  • Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. 
  • Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. 
  • An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS). 
  • Anticoagulation: indications and risk classification schemes. 
  • Anticoagulation: managing adverse events in patients receiving anticoagulation and perioperative care. 
  • Anticoagulation: monitoring of patients receiving anticoagulation. 
  • Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. 
  • Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. 
  • Apixaban versus warfarin in patients with atrial fibrillation. 
  • Association Between Inappropriately Dosed Anticoagulation Therapy With Stroke Severity and Outcomes in Patients With Atrial Fibrillation. 
  • Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. 
  • Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. 
  • At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). 
  • Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. 
  • Central retinal vein occlusion in patients treated with long-term warfarin sodium (Coumadin) for anticoagulation. 
  • Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients. 
  • Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. 
  • Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry. 
  • Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. 
  • Database comparison of the adult-to-adult living donor liver transplantation cohort study (A2ALL) and the SRTR U.S. Transplant Registry. 
  • Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. 
  • Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding. 
  • Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. 
  • Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. 
  • Does distance modify the effect of self-testing in oral anticoagulation? 
  • Does this patient with liver disease have cirrhosis? 
  • Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. 
  • Effect of home testing of international normalized ratio on clinical events. 
  • Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. 
  • Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. 
  • End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. 
  • Estimation of the warfarin dose with clinical and pharmacogenetic data. 
  • Factors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillation. 
  • Factors influencing plasma transfusion practices in paediatric intensive care units around the world. 
  • First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. 
  • Genetic-based dosing in orthopedic patients beginning warfarin therapy. 
  • Higher mortality in pediatric and adult trauma patients with traumatic coagulopathy, using age-adjusted diagnostic criteria. 
  • Home monitoring of warfarin effects. 
  • How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. 
  • Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. 
  • Impact of prophylactic oseltamivir on INR in patients on stable warfarin therapy. 
  • Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. 
  • Increased risk of deep venous thrombosis with endovascular cooling in patients with traumatic head injury. 
  • Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans. 
  • Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. 
  • Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy. 
  • International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. 
  • International normalized ratio. 
  • Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. 
  • Intraoperative Administration of 4-Factor Prothrombin Complex Concentrate Reduces Blood Requirements in Cardiac Transplantation. 
  • Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. 
  • Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. 
  • Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 
  • Managing oral anticoagulant therapy. 
  • Meta-Analysis of Genotype-Guided Versus Standard Dosing of Vitamin K Antagonists. 
  • Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. 
  • Oral anticoagulant therapy for the prevention of stroke. 
  • Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. 
  • Patterns of anticoagulation following bioprosthetic valve implantation: observations from ANSWER. 
  • Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. 
  • Perioperative hemostatic management of patients treated with vitamin K antagonists. 
  • Perioperative management of patients on chronic antithrombotic therapy. 
  • Pharmacist-managed international normalized ratio patient self-testing is associated with increased time in therapeutic range in patients with left ventricular assist devices at an academic medical center. 
  • Pharmacologic prophylaxis, postoperative INR, and risk of venous thromboembolism after hepatectomy. 
  • Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies. 
  • Postdischarge international normalized ratio testing and long-term clinical outcomes of patients with heart failure receiving warfarin: findings from the ADHERE registry linked to Medicare claims. 
  • Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation. 
  • Predictors of Warfarin Time in Therapeutic Range after Continuous-Flow Left Ventricular Assist Device. 
  • Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation. 
  • Prophylactic correction of the international normalized ratio in neurosurgery: a brief review of a brief literature. 
  • Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. 
  • Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. 
  • Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal. 
  • Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. 
  • Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. 
  • Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care. 
  • Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. 
  • Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. 
  • Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. 
  • Retrospective analysis of the incidence of epidural haematoma in patients with epidural catheters and abnormal coagulation parameters. 
  • Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage. 
  • Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. 
  • Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. 
  • Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. 
  • Safety of warfarin dosing in the intensive care unit following the Fontan procedure. 
  • Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. 
  • Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. 
  • Stroke prevention in atrial fibrillation: Closing the gap. 
  • The effects of argatroban on thrombin generation and hemostatic activation in vitro. 
  • The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial. 
  • The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS). 
  • The safety of warfarin therapy in the nursing home setting. 
  • Thrombosis and the antiphospholipid syndrome. 
  • Time in Therapeutic Range Significantly Impacts Survival and Adverse Events in Destination Therapy Patients. 
  • Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. 
  • Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. 
  • Warfarin or aspirin for recurrent ischemic stroke. 
  • Warfarin therapy does not increase bleeding in patients undergoing heart transplantation. 
  • Which approach to anticoagulation management is best? Illustration of an interactive mathematical model to support informed decision making. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics